Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

[Technological approaches to development of whole-virion inactivated vaccine from recombinant strain against A/H5N1 influenza in the Republic of Kazakhstan].

Kydyrbaev ZhK, Mamadaliev SM, Asanzhanova NN, Tabynov KK, Ryskel'dinova ShZh, Cherviakova OV, Sandybaev NT, Khaĭrullin BM, Kiselev OI.

Zh Mikrobiol Epidemiol Immunobiol. 2012 Sep-Oct;(5):54-9. Russian.

PMID:
23163037
2.

A/H5N1 prepandemic influenza vaccine (whole virion, vero cell-derived, inactivated) [Vepacel®].

Plosker GL.

Drugs. 2012 Jul 30;72(11):1543-57. doi: 10.2165/11209650-000000000-00000. Review.

PMID:
22788239
4.

The avian influenza vaccine Emerflu. Why did it fail?

Young BE, Sadarangani SP, Leo YS.

Expert Rev Vaccines. 2015;14(8):1125-34. doi: 10.1586/14760584.2015.1059760. Epub 2015 Jun 22. Review.

PMID:
26098721
5.

Return of inactivated whole-virus vaccine for superior efficacy.

Furuya Y.

Immunol Cell Biol. 2012 Jul;90(6):571-8. doi: 10.1038/icb.2011.70. Epub 2011 Aug 16. Review.

PMID:
21844883
6.

A/H5N1 prepandemic influenza vaccine (Vepacel®): a guide to its use.

Keating GM, Plosker GL, Lyseng-Williamson KA.

BioDrugs. 2012 Dec 1;26(6):425-30. doi: 10.2165/11209740-000000000-00000. Review.

PMID:
23106407
7.

Safety and immunogenicity of Sinovac's prototype pandemic influenza H5N1 vaccines: a review on clinical trials.

Qiu YZ, Yin WD.

Influenza Other Respir Viruses. 2008 Nov;2(6):237-42. doi: 10.1111/j.1750-2659.2008.00067.x. Review.

8.

Clinical vaccine development for H5N1 influenza.

Clegg CH, Rininger JA, Baldwin SL.

Expert Rev Vaccines. 2013 Jul;12(7):767-77. doi: 10.1586/14760584.2013.811178. Review.

PMID:
23885822
9.

[Introduction to novel vaccine adjuvants and their role in influenza vaccination].

Haensler J.

Ann Pharm Fr. 2013 Mar;71(2):104-8. doi: 10.1016/j.pharma.2013.01.003. Epub 2013 Mar 1. Review. French.

PMID:
23537411
10.

New technologies for influenza vaccines.

Dormitzer PR, Tsai TF, Del Giudice G.

Hum Vaccin Immunother. 2012 Jan;8(1):45-58. doi: 10.4161/hv.8.1.18859. Epub 2012 Jan 1. Review.

PMID:
22251994
11.

Adjuvanted influenza vaccines.

Principi N, Esposito S.

Hum Vaccin Immunother. 2012 Jan;8(1):59-66. doi: 10.4161/hv.8.1.18011. Epub 2012 Jan 1. Review.

PMID:
22252004
12.

Influenza vaccines: from whole virus preparations to recombinant protein technology.

Huber VC.

Expert Rev Vaccines. 2014 Jan;13(1):31-42. doi: 10.1586/14760584.2014.852476. Review.

PMID:
24192014
13.

[Cultural influenza vaccines].

Gendon IuZ.

Vopr Virusol. 2002 Nov-Dec;47(6):4-11. Review. Russian.

PMID:
12508674
14.

Use of computational and recombinant technologies for developing novel influenza vaccines.

Wong TM, Ross TM.

Expert Rev Vaccines. 2016;15(1):41-51. doi: 10.1586/14760584.2016.1113877. Epub 2015 Nov 23. Review.

PMID:
26595182
15.

[Virus-like particles--a new strategy for production of vaccines against influenza virus].

Petukhova NV, Ivanov PA, Migunov AI.

Vopr Virusol. 2013 Mar-Apr;58(2):10-4. Review. Russian.

PMID:
23785764
16.

Influenza vaccines: present and future.

Palese P, García-Sastre A.

J Clin Invest. 2002 Jul;110(1):9-13. Review. No abstract available.

17.

[Reflection on the history and development of influenza surveillance].

Shu YL.

Zhonghua Liu Xing Bing Xue Za Zhi. 2011 Apr;32(4):334-6. Review. Chinese. No abstract available.

PMID:
21569661

Supplemental Content

Support Center